778 related articles for article (PubMed ID: 32710418)
21. Efficient Editing of the Nuclear
Guzmán-Zapata D; Sandoval-Vargas JM; Macedo-Osorio KS; Salgado-Manjarrez E; Castrejón-Flores JL; Oliver-Salvador MDC; Durán-Figueroa NV; Nogué F; Badillo-Corona JA
Int J Mol Sci; 2019 Mar; 20(5):. PubMed ID: 30871076
[TBL] [Abstract][Full Text] [Related]
22. PpCas9 from Pasteurella pneumotropica - a compact Type II-C Cas9 ortholog active in human cells.
Fedorova I; Vasileva A; Selkova P; Abramova M; Arseniev A; Pobegalov G; Kazalov M; Musharova O; Goryanin I; Artamonova D; Zyubko T; Shmakov S; Artamonova T; Khodorkovskii M; Severinov K
Nucleic Acids Res; 2020 Dec; 48(21):12297-12309. PubMed ID: 33152077
[TBL] [Abstract][Full Text] [Related]
23. Fusion guide RNAs for orthogonal gene manipulation with Cas9 and Cpf1.
Kweon J; Jang AH; Kim DE; Yang JW; Yoon M; Rim Shin H; Kim JS; Kim Y
Nat Commun; 2017 Nov; 8(1):1723. PubMed ID: 29167440
[TBL] [Abstract][Full Text] [Related]
24. Bacterial Genome Editing with CRISPR-Cas9: Taking Clostridium beijerinckii as an Example.
Zhang ZT; Jiménez-Bonilla P; Seo SO; Lu T; Jin YS; Blaschek HP; Wang Y
Methods Mol Biol; 2018; 1772():297-325. PubMed ID: 29754236
[TBL] [Abstract][Full Text] [Related]
25. CRISPR-Cas9 Genome Editing in Human Cell Lines with Donor Vector Made by Gibson Assembly.
Sahoo N; Cuello V; Udawant S; Litif C; Mustard JA; Keniry M
Methods Mol Biol; 2020; 2115():365-383. PubMed ID: 32006411
[TBL] [Abstract][Full Text] [Related]
26. Gene Editing in B-Lymphoma Cell Lines Using CRISPR/Cas9 Technology.
Bai B; Myklebust JH; Wälchli S
Methods Mol Biol; 2020; 2115():445-454. PubMed ID: 32006416
[TBL] [Abstract][Full Text] [Related]
27. Target-Specific Precision of CRISPR-Mediated Genome Editing.
Chakrabarti AM; Henser-Brownhill T; Monserrat J; Poetsch AR; Luscombe NM; Scaffidi P
Mol Cell; 2019 Feb; 73(4):699-713.e6. PubMed ID: 30554945
[TBL] [Abstract][Full Text] [Related]
28. SeqCor: correct the effect of guide RNA sequences in clustered regularly interspaced short palindromic repeats/Cas9 screening by machine learning algorithm.
Liu X; Yang Y; Qiu Y; Reyad-Ul-Ferdous M; Ding Q; Wang Y
J Genet Genomics; 2020 Nov; 47(11):672-680. PubMed ID: 33451939
[TBL] [Abstract][Full Text] [Related]
29. Engineering Introns to Express RNA Guides for Cas9- and Cpf1-Mediated Multiplex Genome Editing.
Ding D; Chen K; Chen Y; Li H; Xie K
Mol Plant; 2018 Apr; 11(4):542-552. PubMed ID: 29462720
[TBL] [Abstract][Full Text] [Related]
30. CRISPR-Cas "Non-Target" Sites Inhibit On-Target Cutting Rates.
Moreb EA; Hutmacher M; Lynch MD
CRISPR J; 2020 Dec; 3(6):550-561. PubMed ID: 33346713
[TBL] [Abstract][Full Text] [Related]
31. Refined sgRNA efficacy prediction improves large- and small-scale CRISPR-Cas9 applications.
Labuhn M; Adams FF; Ng M; Knoess S; Schambach A; Charpentier EM; Schwarzer A; Mateo JL; Klusmann JH; Heckl D
Nucleic Acids Res; 2018 Feb; 46(3):1375-1385. PubMed ID: 29267886
[TBL] [Abstract][Full Text] [Related]
32. Chromatin accessibility and guide sequence secondary structure affect CRISPR-Cas9 gene editing efficiency.
Jensen KT; Fløe L; Petersen TS; Huang J; Xu F; Bolund L; Luo Y; Lin L
FEBS Lett; 2017 Jul; 591(13):1892-1901. PubMed ID: 28580607
[TBL] [Abstract][Full Text] [Related]
33. Optical Control of Genome Editing by Photoactivatable Cas9.
Otabe T; Nihongaki Y; Sato M
Methods Mol Biol; 2021; 2312():225-233. PubMed ID: 34228293
[TBL] [Abstract][Full Text] [Related]
34. Maximizing CRISPR/Cas9 phenotype penetrance applying predictive modeling of editing outcomes in Xenopus and zebrafish embryos.
Naert T; Tulkens D; Edwards NA; Carron M; Shaidani NI; Wlizla M; Boel A; Demuynck S; Horb ME; Coucke P; Willaert A; Zorn AM; Vleminckx K
Sci Rep; 2020 Sep; 10(1):14662. PubMed ID: 32887910
[TBL] [Abstract][Full Text] [Related]
35. The length of guide RNA and target DNA heteroduplex effects on CRISPR/Cas9 mediated genome editing efficiency in porcine cells.
Lv J; Wu S; Wei R; Li Y; Jin J; Mu Y; Zhang Y; Kong Q; Weng X; Liu Z
J Vet Sci; 2019 May; 20(3):e23. PubMed ID: 31161741
[TBL] [Abstract][Full Text] [Related]
36. Recent advances in chemical modifications of guide RNA, mRNA and donor template for CRISPR-mediated genome editing.
Chen Q; Zhang Y; Yin H
Adv Drug Deliv Rev; 2021 Jan; 168():246-258. PubMed ID: 33122087
[TBL] [Abstract][Full Text] [Related]
37. Shooting the messenger: RNA-targetting CRISPR-Cas systems.
Zhu Y; Klompe SE; Vlot M; van der Oost J; Staals RHJ
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29748239
[TBL] [Abstract][Full Text] [Related]
38. Nonviral Genome Editing Based on a Polymer-Derivatized CRISPR Nanocomplex for Targeting Bacterial Pathogens and Antibiotic Resistance.
Kang YK; Kwon K; Ryu JS; Lee HN; Park C; Chung HJ
Bioconjug Chem; 2017 Apr; 28(4):957-967. PubMed ID: 28215090
[TBL] [Abstract][Full Text] [Related]
39. Battling CRISPR-Cas9 off-target genome editing.
Li D; Zhou H; Zeng X
Cell Biol Toxicol; 2019 Oct; 35(5):403-406. PubMed ID: 31313008
[No Abstract] [Full Text] [Related]
40. Advances in Accurate Microbial Genome-Editing CRISPR Technologies.
Lee HJ; Lee SJ
J Microbiol Biotechnol; 2021 Jul; 31(7):903-911. PubMed ID: 34261850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
